Lv1
70 积分 2021-09-06 加入
Mechanisms of primary resistance to immune checkpoint inhibitors in NSCLC
1天前
待确认
The Role of Immunotherapy in Triple-Negative Breast Cancer (TNBC)
8天前
已完结
Safety and Effectiveness of Immune Checkpoint Inhibitors in Older Patients with Cancer: A Systematic Review of 48 Real-World Studies
28天前
已完结
Mechanisms regulating PD-L1 expression in cancers and associated opportunities for novel small-molecule therapeutics
1个月前
已完结
Immunotherapy in EGFR-Mutant Non–Small Cell Lung Cancer: End of the Road or the First Chapter?
3个月前
已完结
Sotorasib for previously treated colorectal cancers with KRASG12C mutation (CodeBreaK100): a prespecified analysis of a single-arm, phase 2 trial
4个月前
已完结
Sotorasib versus docetaxel for previously treated non-small-cell lung cancer with KRASG12C mutation: a randomised, open-label, phase 3 trial
4个月前
已完结
Breakthrough in RAS targeting with pan-RAS(ON) inhibitors RMC-7977 and RMC-6236
4个月前
已完结
Therapeutic developments in pancreatic cancer
4个月前
已完结
Combinatorial strategies to target RAS-driven cancers
4个月前
已完结
皖公网安备34019202002308
